

Re: - R55  
7/16/87



**Stonewall Jackson  
MEMORIAL HOSPITAL** WESTON, WEST VIRGINIA 26452

TELEPHONE 304-269-3000

June 23, 1987

87 JUL 16 A9:56

U. S. Nuclear Regulatory Commission  
Radioisotopes Licensing Section  
Region II  
101 Marietta Street, N.W.  
Suite 2900  
Atlanta, Georgia 30323

Re: Amendment to NRC Radioactive Materials License #47-18080-01

Gentlemen:

We request amendment to our Nuclear Regulatory Commission radioactive materials license #47-18080-01 for the following:

1. Addition of seven physicians as authorized users to our NRC radioactive materials license. Please see attached.
2. Addition of Douglas G. Burnette, Jr., M.D., as Radiation Safety Officer, and Chairman of our Radiation Safety Committee. For training and experience of Dr. Burnette, please reference Fairmont General Hospital, Fairmont, West Virginia, NRC radioactive materials license #47-17929-01.
3. Delete Ray A. Harron, M.D., as authorized user and Radiation Safety Officer from our NRC radioactive materials license.

We trust the above information is sufficient to grant our request for amendment and look forward to receipt of that document. Enclosed is our check for \$120 to cover the amendment processing fees.

Sincerely,

*Douglas G. Burnette, Jr., MD*

Douglas G. Burnette, Jr., M.D.  
Radiation Safety Officer

:jms

Enclosures

Log	Jul-5-II
Permit	
Check	6/21
Fee	\$120
File	7C
And	
1/22/87	
7/22/87	
Russell	

87 JUL 22 10:40  
51680

RECEIVED

8801290059 870730  
REG1 LIC30  
47-18080-01 PDR

OFFICIAL COPY

AUTHORIZED USER(S)

AUTHORIZED USER(S)

AUTHORIZATION

\*M.I. McClain, M.D.

ALL

\*John C. Turner, M.D.

ALL

\*For training and experience of the above, please reference Fairmont General Hospital, Fairmont, West Virginia, NRC license #47-17929-01.

\*\*Harry G. Kennedy, Jr., M.D.

All groups for which  
he is authorized for

\*\*Douglas G. Burnette, Jr., M.D.

All groups for which  
he is authorized for

\*\*Robert J. Tallaksen, M.D.

All groups for which  
he is authorized for

\*\*Edward F. Downey, Jr., D.O.

All groups for which  
he is authorized for

\*\*Gary D. Marano, M.D.

All groups for which  
he is authorized for

\*\*For training and experience of the above, please reference the attached training and experience forms.

UNITED STATES ATOMIC ENERGY COMMISSION  
APPLICATION FOR BYPRODUCT MATERIAL LICENSE MEDICAL  
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Back of page may be used for comments.

9. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code)

HARRY G. KENNEDY, JR., CDR MC USNR  
283 Horizon Hills Drive  
El Cajon, California 92020

10. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 9 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131	Diagnosis of thyroid function	76	76
	Dilution studies		
	Excretion studies		
	Brain tumor localization		
	Scanning studies	2	2
	Treatment of hyperthyroidism	5	5
	Treatment of cardiac conditions		
	Treatment of thyroid carcinoma	2	2
P-32 Soluble	Treatment of polycythemia		
	Treatment of leukemia		
	Treatment of bone metastases		
	Tumor localization		
	Intracavitary treatment		
Au-198	Interstitial treatment		
	Scanning studies		
Cr-51	Blood determinations	7	7
	Scanning studies		
Co-58 or Co-60	Diagnosis of pernicious anemia		
Co-60	Interstitial treatment		
I-192	Intracavitary treatment		
Co-60 or Cs-137	Teletherapy treatment		
Sr-90	Treatment of superficial diseases of the eye		
Other Isotopes Use back of page			

Key to Column (C) and (D) above

1. Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
2. Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed; (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data; and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

11. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING 25 SEP 72 - 17 NOV 72

12. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF J. E. TURNER, CAPT MC USN

U.S. Naval Hospital  
Bethesda, Maryland 20014

19-02891-05

At

(Institution Name and Address)

(Byproduct Material License Number)

(Signature of Preceptor)

APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL  
SUPPLEMENT A—HUMAN USE

PAGE 4

This page may be used for providing additional information.

Co-57	Schillings Test	3	3
I-125	Plasma Volumes	5	5
Ga-67	Bone Scans	68	68
In-111	CSF	9	9
I-125	T3-T4	1560	1560
Tc-99m	Scanning Studies:		
	Liver	153	153
	Brain	120	120
	Placenta	3	3
	Lung	26	26
	Renal	22	22
	Cardiac	5	5
	Parotid	3	3

Training documentation in the case of:  
Harry G. Kennedy, Jr., M.D.

FORM NRC-313M-SUPPLEMENT A  
(8-78)

U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE  
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

2. STATE OR TERRITORY IN  
WHICH LICENSED TO  
PRACTICE MEDICINE

3. CERTIFICATION

SPECIALTY BOARD  
A

CATEGORY  
B

MONTH AND YEAR CERTIFIED  
C

American Board of Radiology

Diagnostic Radiology

June 1975


4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	National Naval Medical Center Bethesda, MD 20814 Course 7301, Medical Officers Course in	64 (104 total hours)	40
b. RADIATION PROTECTION	Nuclear Medicine and Radioisotope Techniques, 25 September through 17 November 1972.	11	0
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	As above.	27	0
d. RADIATION BIOLOGY	As above.	10	0
e. RADIOPHARMACEUTICAL CHEMISTRY	As above.	33	0

E.D. Silverman, LCDR, MC, USN

*E. Silverman* LCDR

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Dr. Kennedy spent 3 months using all radioisotopes in the Nuclear Medicine Clinic at Naval Hospital, San Diego, California, December 1972-July 1973.				
 G. D. McKNIGHT Captain, Medical Corps, U. S. Navy Head, Department of Radiology Naval Hospital, Bethesda, Maryland				

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

Harry G. Kennedy, Jr. M.D.

## STREET ADDRESS

1000 Locust Avenue

## CITY

Fairmont

## STATE

WV

## ZIP CODE

26554

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	111	Tc-99m Hepatobiliary Scan = 47
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	2	
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS	25	
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	26	
OTHER			
Tc-99m	BRAIN IMAGING	109	
	CARDIAC IMAGING	15	
	THYROID IMAGING	117	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING	21	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	174	
	LUNG IMAGING	141	
	BONE IMAGING	258	
OTHER	Tc-99m Renal Imaging	20	

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM	7	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192 Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	50	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	150	
Other			
Ga-67	Gallium Scans	3	
Tl-201	Thallium Scans	9	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

September 1982 to March 1984      1500 hours

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

John C. Turner, M.D.

b. NAME OF INSTITUTION

The Monongalia General Hospital

c. MAILING ADDRESS

J.D. Anderson Drive

d. CITY

Morgantown, West Virginia 26505

e. PRECEPTOR'S SIGNATURE

f. PRECEPTOR'S NAME (Please type or print)

John C. Turner, M.D.

g. DATE

April 11, 1984

MATERIALS LICENSE NUMBER(S)

47-16259-01



DEPARTMENT OF THE NAVY  
NAVAL HOSPITAL  
NAVAL MEDICAL COMMAND, NATIONAL CAPITAL REGION  
BETHESDA, MARYLAND 20814

IN REPLY REFER TO  
2 August 1984

The Monongalia General Hospital  
Sue E. DeVincent, CMT  
Department Head, Nuclear Medicine  
Morgantown, West Virginia 26505


RE: Dr. Harry Kennedy; additional documentation of training in Nuclear Medicine

Dear Ms. DeVincent:

During the three months Dr. Kennedy spent in the Nuclear Medicine Clinic at San Diego Naval Hospital there was an additional 25-30 hours spent in a didactic course of physics and related Nuclear Medicine topics.

Sincerely,

G. Dean McKnight  
Captain, Medical Corps, U.S. Navy  
Chairman, Radiology Department



Nuclear Medicine experience of Harry G. Kennedy, Jr. M.D. since 1975

I completed my Diagnostic Radiology residency in July 1974 and spent one year (1974-1975) as a Diagnostic Radiologist on the staff of the San Diego Naval Hospital, San Diego, California.

From September 1975 until April 1978, I was a radiologist at General Hospital of Virginia Beach, Virginia Beach, Virginia with the group Wallace, Seim and Hughes. For those two and one half years I was responsible for all Nuclear Medicine studies every fourth week. On arriving at the General Hospital of Virginia Beach I submitted my curriculum vitae for inclusion on their license. At GHVB we were averaging approximately 15 Nuclear Medicine studies per day including the full gamut of technetium studies as well as I-131 therapeutic and diagnostic studies, and Gallium 67.

From May 1978 until July 1982, I was the Chief of Diagnostic Radiology at Bethesda Naval Hospital, Bethesda, Maryland. The Nuclear Medicine division was under my direct supervision. The Nuclear Medicine Department of Bethesda Naval Hospital averaged 25 Nuclear Medicine studies per day.

From July 1982 until the present I am an employee of Radiological Consultants Association, Fairmont, West Virginia and have been responsible for the Nuclear Medicine studies at Fairmont General Hospital, Fairmont, West Virginia as well as Monongalia General Hospital, Morgantown, West Virginia. I would estimate that I read an average of 10 studies per day.

If you desire any further information please feel free to write or call me.

Sincerely,

*Harry G. Kennedy, Jr., M.D.*  
Harry G. Kennedy, Jr. M.D.

TRAINING AND EXPERIENCE  
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

DOUGLAS G. BURNETTE, JR., M.D.

2. STATE OR TERRITORY IN  
WHICH LICENSED TO  
PRACTICE MEDICINE  
MARYLAND

## 3. CERTIFICATION

SPECIALTY BOARD  
ACATEGORY  
BMONTH AND YEAR CERTIFIED  
C

AMERICAN BOARD OF RADIOLOGY

GENERAL DIAGNOSTIC

JUNE 1960

## 4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING  
ALOCATION AND DATE(S) OF TRAINING  
B

## TYPE AND LENGTH OF TRAINING

LECTURE/  
LABORATORY  
COURSES  
(Hours)  
CSUPERVISED  
LABORATORY  
EXPERIENCE  
(Hours)  
Da. RADIATION PHYSICS AND  
INSTRUMENTATIONNATIONAL NAVAL MEDICAL CENTER  
BETHESDA, MARYLAND 20014  
COURSE # 79002

82

19

b. RADIATION PROTECTION

08Jan to 09 Mar 1979

SAME AS ABOVE

26

0

c. MATHEMATICS PERTAINING TO  
THE USE AND MEASUREMENT  
OF RADIOACTIVITY

SAME AS ABOVE

28

3

d. RADIATION BIOLOGY

SAME AS ABOVE

20

0

e. RADIOPHARMACEUTICAL  
CHEMISTRY

SAME AS ABOVE

35

0

## 5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE

MAXIMUM AMOUNT

WHERE EXPERIENCE WAS GAINED

DURATION OF EXPERIENCE

TYPE OF USE

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

DOUGLAS G. BURNETTE, JR., M.D.

## STREET ADDRESS

19849 BAZZELLTON PLACE

## CITY

GAITHERSBURG, MARYLAND

## STATE

## ZIP CODE

20760

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	11	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	2	
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES	400	
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	14	
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	4	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	2	
OTHER			
Tc-99m	BRAIN IMAGING	60	
	CARDIAC IMAGING	31	
	THYROID IMAGING	33	
	SALIVARY GLAND IMAGING	2	
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	107	
	LUNG IMAGING	10	
	BONE IMAGING	115	
OTHER	KIDNEY IMAGING	25	

# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	2	
	TREATMENT OF HYPERTHYROIDISM	6	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or In-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	10	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	10	
Other			

## 2. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

8 JANUARY 1979 to FEBRUARY 1979 --- 200 HOURS BASIC SCIENCES

7 FEBRUARY 1979 to 9 MARCH 1979 --- 160 HOURS CLINICAL IMAGING TRAINING

## 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

### a. NAME OF SUPERVISOR

R. F. KIEPFER, CAPT, MC., USN

### b. NAME OF INSTITUTION

NATIONAL NAVAL MEDICAL CENTER

### c. MAILING ADDRESS

NUCLEAR MEDICINE DEPARTMENT

### d. CITY

BETHESDA, MARYLAND 20014

## 5. PRECEPTOR'S SIGNATURE

*J. P. Smith*

## 7. PRECEPTOR'S NAME (Please type or print)

J. P. SMITH  
CAPT MC USN

## 3. DATE

24 January 1983

## 5. MATERIALS LICENSE NUMBER(S)

19-02891-05

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Douglas George Burnette, Jr. M.D.

STREET ADDRESS

209-B Morgan Drive

CITY

Morgantown

STATE

WV

ZIP CODE

26505

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		Other studies using $^{99m}\text{Tc}$ compounds:  GE reflux 24 Meckel's scan 80 Cystogram 306 Diuretic renogram 66 GFR 113
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	6	
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY $^{111}\text{In}$ -DTPA	55	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING	105	
	CARDIAC IMAGING	79	
	THYROID IMAGING	72	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	342	
	LUNG IMAGING	47	
	BONE IMAGING	671	
OTHER	Hepatobiliary	97	

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

Douglas George Burnette, Jr. M.D.

## STREET ADDRESS

209-B Morgan Drive

## CITY

Morgantown

## STATE

WV

## ZIP CODE

26505

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING	2	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	10	
	LUNG IMAGING		
	BONE IMAGING	15	
OTHER			

Meckel's Scan 3  
Renal Scan 20  
Cystogram 18  
Gallium Scan 8

# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheet.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

01OCT81 through 31MAY83

Approximately 500 hours

## 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

### a. NAME OF SUPERVISOR

John P. Smith, CAPT (MC) USN

### b. NAME OF INSTITUTION

National Naval Medical Center

### c. MAILING ADDRESS

Bethesda, Maryland 20814

### d. CITY

## 5. PRECEPTOR'S SIGNATURE

John P. Smith

## 7. PRECEPTOR'S NAME (Please type or print)

John P. Smith  
CAPT (MC) USN

## 8. DATE

20 October 1983

## 5. MATERIALS LICENSE NUMBER(S)

NRC # 19-02891-05

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

Douglas George Burnette, Jr. M.D.

## STREET ADDRESS

209-B Morgan Drive

## CITY

Morgantown,

## STATE

WV

## ZIP CODE

26505

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	65	Tc-99m Hepatobiliary Scans = 25
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS	6	
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	9	
OTHER			
Tc-99m	BRAIN IMAGING	16	
	CARDIAC IMAGING	21	
	THYROID IMAGING	72	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING	11	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	59	
	LUNG IMAGING	38	
	BONE IMAGING	132	
OTHER	Tc-99m Renal Imaging	7	

# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM	10	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
	TELE THERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	20	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	100	
Other	Ga-67 Gallium Scans	2	
	Tl-201 Thallium Scans	13	

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

July 1983 to March 1984

1000 hours

## 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

John C. Turner, M.D.

b. NAME OF INSTITUTION

The Monongalia General Hospital

c. MAILING ADDRESS

J.D. Anderson Drive


d. CITY

Morgantown, West Virginia 26505

5. MATERIALS LICENSE NUMBER(S)

47-16259-01

6. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

John C. Turner, M.D.

8. DATE

April 11, 1984

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

LT Robert J. Tallaksen, MC, USN

## STREET ADDRESS

National Naval Medical Center  
Bethesda, Maryland 20014

## CITY

## STATE

## ZIP CODE

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	56	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	2	
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES	928	
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	65	
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	1	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING	66	Tc-99m--Meckels Scan--1 Tc-99m--Parotid Scan--5
	CARDIAC IMAGING	15	
	THYROID IMAGING	10	
	SALIVARY GLAND IMAGING	5	
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	90	
	LUNG IMAGING	13	
	BONE IMAGING	110	
OTHER			

Certified to be a true copy.

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS <i>(Additional information or comments may be submitted in duplicate on separate sheets.)</i>
A	B	C	D
P-32 (Colloid)	TREATMENT OF POLYCYTHLEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloid)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Au-199	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
	TELETHERAPY TREATMENT		
Sr-90 or Cs-137	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	1 *	* Milked one Mo-99/Tc-99m generator--watched second elution  ** prepared two reagent kits --watched a third being prepared.
Sn-112/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	2 **	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

02 October 1978 to 28 October 1978 200 hours Basic Sciences  
30 October 1978 to 22 November 1978 140 hours Clinical Radioisotope Training.

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

A. NAME OF SUPERVISOR

B. F. KIEPFER, CAPT, MC, USN

C. NAME OF INSTITUTION

National Naval Medical Center

D. MAILING ADDRESS

Bethesda, Maryland 20014

E. CITY

5. PRECEPTOR'S SIGNATURE

*[Handwritten Signature]*

7. PRECEPTOR'S NAME (Please type or print)

B.F. KIEPFER, CAPT, MC, USN  
Director, Nuclear Medicine Department

8. DATE

22 November 1978

9. MATERIALS LICENSE NUMBER(S)

10-01801-05

FORM 100-100 SUPPLEMENT D  
(6-70)

Certified to be a true copy.

*[Handwritten Signature]*  
T. W. Hine, LCDR, MC, USN

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

## FULL NAME

Robert Tallaksen, LCDR, MC, USN

## STREET ADDRESS

Radiology Department  
Naval Hospital, NMCNCR

## CITY

Bethesda

## STATE

MD

## ZIP CODE

20814

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	06	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	04	
	LIVER FUNCTION STUDIES	00	
	FAT ABSORPTION STUDIES	00	
	KIDNEY FUNCTION STUDIES	03	
	IN VITRO STUDIES	3116	
OTHER		--	
I-125	DETECTION OF THROMBOSIS	00	
I-131	THYROID IMAGING	10	
P-32	EYE TUMOR LOCALIZATION	00	
Se-75	PANCREAS IMAGING	00	
Yb-169	CISTERNOGRAPHY	00	
Xe-127 <del>Xe-133</del>	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	12	
OTHER	Tc-99m Cisternography	03	
Tc-99m	BRAIN IMAGING	35	
	CARDIAC IMAGING	20	
	THYROID IMAGING	25	
	SALIVARY GLAND IMAGING	03	
	BLOOD POOL IMAGING	00	
	PLACENTA LOCALIZATION	00	
	LIVER AND SPLEEN IMAGING	89	
	LUNG IMAGING	18	
	BONE IMAGING	146	
OTHER	Tc-99m Kidney Imaging	39	


# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	00	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	00	
I-131	TREATMENT OF THYROID CARCINOMA	02	
	TREATMENT OF HYPERTHYROIDISM	04	
Au-198	INTRACAVITARY TREATMENT	00	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	00	
	INTRACAVITARY TREATMENT	00	
I-125 or Ir-192	INTERSTITIAL TREATMENT	00	
	TELE THERAPY TREATMENT	00	
Sr-90	TREATMENT OF EYE DISEASE	00	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	06	
Sn-113/ In-113m	GENERATOR	00	
Tc-99m	REAGENT KITS	18	
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

500 hours of clinical training received during a total of 3 months spent in rotations in Nuclear Medicine as part of a Diagnostic Radiology Residency during the period January through June 1979.

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		6. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR J. P. SMITH, CAPT, MC, USN		 E. D. SILVERMAN LCDR, MC, USN	
b. NAME OF INSTITUTION Naval Hospital, NHCNCR			
c. MAILING ADDRESS Radiology Department			
d. CITY Bethesda, MD 20814		7. PRECEPTOR'S NAME (Please type or print) E. D. SILVERMAN LCDR, MC, USN	
5. MATERIALS LICENSE NUMBER(S) 19-02891-05		8. DATE 4 May 1984	

1520

22 November 1978

Dear Dr. Tallaksen:

The following information is enclosed for your records and for use when applying for a NRC By-Products Materials License.

U.S. Form 100-31 (2-5-64) Supplement A (7-77) 19 GPO 70

## 4. TRAINING RECEIVED IN FASCIS RADICAL GUN HANDLING TRAINING:

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	DATE OF COMPLETION C	DATE OF COMPLETION D
1. RADIATION PHYSICS AND CALCULATION	National Naval Med. Ctr. Bethesda, Md. 20014 Course # 7901 20Oct-22Nov 1978	03	22
2. RADIATION PROTECTION	SAA	30	
3. MATHEMATICS PERTAINING TO THE USE AND MANAGEMENT OF RADIOSISOTOPES	SAA	21	4
4. RADIATION BIOLOGY	SAA	21	
5. ENVIRONMENTAL PHARMACEUTICAL CHEMISTRY	SAA	29	10

The training and experience indicated above was obtained under the supervision of:

Richard F. Knapton, H.M.  
CAPT (MC) USN  
Head, Nuclear Medicine  
National Naval Medical Center

Classified to be a true copy.

T.W. Hinz, CDR, MC, USN

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

## 1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

EDWARD F. DOWNEY JR. D.O.

STREET ADDRESS

7207 Indian Summer Lane

CITY

STATE

ZIP CODE

Frederick,

Md.

21701

## KEY TO COLUMN C

## PERSONAL PARTICIPATION SHOULD CONSIST OF:

1. Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2. Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 OR I-125	DIAGNOSIS OF THYROID FUNCTION	32	<sup>99m</sup> Tc gastric emptying and reflux studies - 25
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	2	
	LIVER FUNCTION STUDIES	0	
	FAT ABSORPTION STUDIES	0	
	KIDNEY FUNCTION STUDIES	0	
	IN VITRO STUDIES	0	
OTHER			GI bleeding - 11
I-125	DETECTION OF THROMBOSIS	0	Meckles scans - 2
I-131	THYROID IMAGING	4	Testicular scans - 2
P-32	EYE TUMOR LOCALIZATION	0	VCUG - 7
Sr-75	PANCREAS IMAGING	0	
Yb-169	CISTERNOGRAPHY	0	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	22	
OTHER	<sup>111</sup> In cisternography	4	
Tc-99m	BRAIN IMAGING	16	
	CARDIAC IMAGING	64	
	THYROID IMAGING	45	
	SALIVARY GLAND IMAGING	2	
	BLOOD POOL IMAGING	41	
	PLACENTA LOCALIZATION	0	
	LIVER AND SPLEEN IMAGING	121	
	LUNG IMAGING	38	
	BONE IMAGING	242	
OTHER			


# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	0	
P-32 (Colloid)	INTRACAVITARY TREATMENT	0	
I-131	TREATMENT OF THYROID CARCINOMA	4	
	TREATMENT OF HYPERTHYROIDISM	7	
Au-198	INTRACAVITARY TREATMENT	0	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	0	
	INTRACAVITARY TREATMENT	0	
I-125 or Ir-192	INTERSTITIAL TREATMENT	0	
Co-60 or Cs-137	TELE THERAPY TREATMENT	0	
Sr-90	TREATMENT OF EYE DISEASE	0	
	RADIOPHARMACEUTICAL PREPARATION	3	
Mo-99/ Tc-99m	GENERATOR	3	
Sn-113/ In-113m	GENERATOR	1	
Tc-99m	REAGENT KITS	6	
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

A. Clinical Rotation In Nuc. Med.-1Dec-31Dec 81& 1Apr-30Apr 82 - 400hrs.  
 B. Staff& consultation work in Nuc. Med.- 5Jul 82- 1Mar 83 - 200hrs.  
 C. Formal Basic Science & Clinical Training- 17Feb- 10Apr 81  
     Basic Science - 240hrs.  
     Clinical Training - 120hrs.

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		6. PRECEPTOR'S SIGNATURE 	
a. NAME OF SUPERVISOR Peter E. Nielsen M.D.		7. PRECEPTOR'S NAME (Please type or print) John P. Smith M.D.  CAPT, MC, USN	
b. NAME OF INSTITUTION NNMC, Bethesda, Md.			
c. MAILING ADDRESS Department of Radiology, NNMC Bethesda, Md. 20814			
5. MATERIALS LICENSE NUMBER(S) 19-02891-05		8. DATE 1 March 1983	

TRAINING AND EXPERIENCE  
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1 NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

EDWARD F. DOWNEY JR., D.O.

2 STATE OR TERRITORY IN  
WHICH LICENSED TO  
PRACTICE MEDICINE  
PA., MD., W.V.

## 3. CERTIFICATION

SPECIALTY BOARD  
ACATEGORY  
BMONTH AND YEAR CERTIFIED  
C

AMERICAN BOARD OF RADIOLOGY

DIAGNOSTIC RADIOLOGY

JUNE 1982

## 4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE / LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
SEE	ATTACHED		
a. RADIATION PHYSICS AND INSTRUMENTATION			
b. RADIATION PROTECTION			
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY			
d. RADIATION BIOLOGY			
e. RADIOPHARMACEUTICAL CHEMISTRY			

## 5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
$^{99m}\text{Tc}$	4.14 Ci	NNMC, Bethesda, Md.	17 Feb 81-1 Mar 83	gen. elut. & kit prep
$^{99}\text{Mo}$	4.14 Ci	" " "	" "	$^{99m}\text{Tc}/^{99}\text{Mo}$ gen.
$^{131}\text{I}$	150 mCi	" " "	" "	Tx thyroid Ca, hyper- thyroidism & function
$^{201}\text{Tl}$	10 mCi	" " "	" "	cardiac testing
$^{67}\text{Ga}$	15 mCi	" " "	" "	soft tissue imaging
$^{111}\text{In}$	10 mCi	" " "	" "	cisternography
$^{127}\text{Xe}$	1 Ci	" " "	" "	vent. scans
$^{133}\text{Xe}$	100 mCi	" " "	" "	" "



NATIONAL NAVAL MEDICAL CENTER

BETHESDA, MARYLAND - 20014

IN REPLY REFER TO  
NNMC:C95:MAT:sb  
Course #8102  
10 April 1981


Edward F. Downey, Jr., LT, MC, USNR  
7887 Briardale Terrace  
Derwood, MD 20855

Dear LT Downey:

The following information is enclosed for your records and for use when  
applying for a NRC By-Products Materials License.  
Part 4 to Form NRC-313M-Supplement A (7-77) 10 CFR 30

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES			
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	NATIONAL NAVAL MEDICAL CENTER, BETHESDA, MD 20014 COURSE #8102 17-Feb 81 to 10 April 1981	84	20
b. RADIATION PROTECTION	SAME AS ABOVE	26	04
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	SAME AS ABOVE	28	—
d. RADIATION BIOLOGY	SAME AS ABOVE	25	—
e. RADIOPHARMACEUTICAL CHEMISTRY	SAME AS ABOVE	53	—

The training and experience indicated above was obtained  
under the supervision of: F. G. Mannarino, CAPT, MC, USN  
NRC License #19-02891-05  
The student attended and successfully completed an  
additional 120 hours of Clinical Nuclear Medicine  
Imaging.

  
J. P. Smith  
CAPT, MC, USN  
Chief, Radiology Service



# The American Board of Radiology

Organized through the cooperation of the  
American College of Radiology, the American Roentgen Ray Society,  
the American Pladium Society, the Radiological Society of North America, the Section  
on Radiology of the American Medical Association and the American Society of Therapeutic Radiologists  
It hereby certifies that

**Gary David Marano, M.D.**

Has pursued an accepted course of graduate study and clinical work, has met certain standards  
and qualifications and has passed the examination conducted under the authority of

The American Board of Radiology

Thereby demonstrating to the satisfaction of the Board that he is qualified to practice the specialty of

Diagnostic Radiology


And further the American Board of Radiology, acting in conjunction and cooperation with

The American Board of Nuclear Medicine

Jointly board formed with the sponsorship of the American Board of Internal Medicine the American  
Board of Pathology, The American Board of Radiology and the Society of Nuclear Medicine

On this the fifth day of June, 1981  
acknowledges Special Competence in

Nuclear Radiology



*Donald L. Jacobson, M.D.*  
President  
American Board of Radiology

*Frank H. L. Finkelschtein*  
Secretary  
American Board of Radiology

*Joseph F. Ryan*  
President  
American Board of Nuclear Medicine

*William H. Bell, M.D.*  
Secretary  
American Board of Nuclear Medicine

*4/2/81*  
*[Signature]*

# PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	5	
P-32 (Colloidal)	INTRACAVITARY TREATMENT	1	
I-131	TREATMENT OF THYROID CARCINOMA	25	
	TREATMENT OF HYPERTHYROIDISM	38	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELE THERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR	52	
Tc-99m	REAGENT KITS	240	
Other  In-111	  Cisternography	  12	

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Total of one year from January, 1978 to April 30, 1981

## 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

### a. NAME OF SUPERVISOR

Orlando F. Gabriele, M.D.

### b. NAME OF INSTITUTION

West Virginia University Hospital

### c. MAILING ADDRESS

Medical Center Drive


### d. CITY

Morgantown, West Virginia 26506

### 5. MATERIALS LICENSE NUMBER(S)

47-01163-20

## 6. PRECEPTOR'S SIGNATURE



## 7. PRECEPTOR'S NAME (Please type or print)

Orlando F. Gabriele, M.D.

## 8. DATE

April 30, 1981

## PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS			KEY TO COLUMN C
FULL NAME			PERSONAL PARTICIPATION SHOULD CONSIST OF:
Gary D. Marano, M.D.			1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
STREET ADDRESS			2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
CITY	STATE	ZIP CODE	3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	3	
	LIVER FUNCTION STUDIES	5	
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	72	
	IN VITRO STUDIES	3840	
OTHER	Gallium-67	60	
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	160	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING	3	
Yb-169	CISTERNOGRAPHY	5	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	102	
OTHER	Thallous Chloride <sup>201</sup> Cardiac	47	
Tc-99m	BRAIN IMAGING	300	
	MYOCARDIAL IMAGING	74	
	THYROID IMAGING	89	
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	720	
	LUNG IMAGING	123	
	BONE IMAGING	970	
OTHER	PIPIDA hepatobiliary	38	